Search

Your search keyword '"Le Guellec S"' showing total 207 results
Start Over Author "Le Guellec S"
207 results on '"Le Guellec S"'

18. Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma

Author

Dufresne, A., primary, Lesluyes, T., additional, Ménétrier-Caux, C., additional, Brahmi, M., additional, Darbo, E., additional, Toulmonde, M., additional, Italiano, A., additional, Mir, O., additional, Le Cesne, A., additional, Le Guellec, S., additional, Valentin, T., additional, Chevreau, C., additional, Bonvalot, S., additional, Robin, Y.M., additional, Coindre, J-M, additional, Caux, C., additional, Blay, J.Y., additional, and Chibon, F., additional

Published
2020
Full Text
View/download PDF

20. Adult Translocation-related soft tissue sarcomas (TRS): Presentation, management and outcome of 2,143 cases confirmed by expert pathologists

Author

Penel, N., primary, Coindre, J.-M., additional, Giraud, A., additional, Terrier, P., additional, Ranchere-Vince, D., additional, Collin, F., additional, Le Guellec, S., additional, Bazille, C., additional, Lae, M., additional, De Pinieux, G., additional, Ray-Coquard, I., additional, Bonvalot, S., additional, Le Cesne, A., additional, Robin, Y.-M., additional, Stoeckle, E., additional, Ducimetiere, F., additional, Toulmonde, M., additional, and Blay, J.-Y., additional

Published
2017
Full Text
View/download PDF

21. Abstract P6-09-05: Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab

Author

Roché, HH, primary, Lafouresse, FF, additional, Filleron, T, additional, Laffont, R, additional, Maisongrosse, V, additional, Pichery, M, additional, Le Guellec, S, additional, Penault-Llorca, F, additional, Lemonnier, J, additional, Lacroix-Triki, M, additional, and Girard, J-P, additional

Published
2017
Full Text
View/download PDF

23. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)

Author

Valentin, T., primary, Le Cesne, A., additional, Ray-Coquard, I., additional, Italiano, A., additional, Decanter, G., additional, Bompas, E., additional, Isambert, N., additional, Thariat, J., additional, Linassier, C., additional, Bertucci, F., additional, Bay, J.O., additional, Bellesoeur, A., additional, Penel, N., additional, Le Guellec, S., additional, Filleron, T., additional, and Chevreau, C., additional

Published
2016
Full Text
View/download PDF

24. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Author

Khalifa, J., primary, Ouali, M., additional, Chaltiel, L., additional, Le Guellec, S., additional, Le Cesne, A., additional, Blay, J-Y, additional, Cousin, P., additional, Chaigneau, L., additional, Bompas, E., additional, Piperno-Neumann, S., additional, Bui-Nguyen, B., additional, Rios, M., additional, Delord, J-P, additional, Penel, N., additional, and Chevreau, C., additional

Published
2015
Full Text
View/download PDF

25. Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib

Author

Barbier, L., Muscari, F., Le Guellec, S., Pariente, A., Otal, P., and Suc, B.

Subjects
Article Subject, neoplasms, digestive system diseases
Abstract

Background. Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases of 2 patients who had surgery after sorafenib. Results. The patients had a large hepatocellular carcinoma in the right liver with venous neoplastic thrombi (1 in the right portal branch, 1 in the right hepatic vein). After 9 months of sorafenib, reassessment showed that tumours had decreased in size with a necrotic component. A right hepatectomy with thrombectomy was performed, and histopathology showed 35% to 60% necrosis. One patient had a recurrence after 6 months and had another liver resection; they are both recurrence-free since then. Conclusion. Sorafenib can downstage hepatocellular carcinoma and thus could represent a bridge to surgery. It may be possible to select patients in good general condition with partial regression of the tumour with sorafenib for a treatment in a curative intent.

Published
2011
Full Text
View/download PDF

27. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab

Author

Maillet, A, Congy Jolivet, N, Le Guellec, S, Vecellio, L, Hamard, S, Courty, Y, Courtois, Anthony, Gauthier, F, Diot, P, Thibault, G, Lemarie, E, and Heuze Vourc' H, N

Subjects
Aggregation, Nebulizer, Cetuximab, Lung cancer, Anticancer antibody, Aerosol
Abstract

Purpose. Despite an increasing interest in the use of inhalation for local delivery of molecules for respiratory diseases and systemic disorders, methods to deliver therapy through air-ways has received little attention for lung cancer treatment. However, inhalation of anticancer drugs is an attractive alternative route to systemic administration which results in limited concentration of the medication in the lungs, and triggers whole-body toxicity. In this study, we investigated the feasibility of nebulization for therapeutic antibodies, a new class of fully-approved anticancer drugs in oncology medicine. Materials and methods. Cetuximab, a chimeric IgG1 targeting the epidermal growth factor receptor (EGER), was nebulized using three types of delivery devices: a jet nebulizer PARI LC+(R), a mesh nebulizer AeronebPro (R) and an ultrasonic nebulizer SYST'AM (R) LS290. Aerosol size distribution was measured using a cascade impactor and aerosol droplets were observed under optical microscopy. The immunological and pharmacological properties of cetuximab were evaluated following nebulization using A431 cells. Results. The aerosol particle clouds generated with the three nebulizers displayed similar aerodynamical characteristics, but the IgG formed aggregates in liquid phase following nebulization with both the jet and ultrasonic devices. Flow cytometry analyses and assays of EGFR-phosphorylation and cell growth inhibitions on A431 demonstrated that both the mesh and the jet nebulizers preserved the binding affinity to EGER and the inhibitory activities of cetuximab. Conclusions. Altogether, our results indicate that cetuximab resists the physical constraints of nebulization, Thus, airway delivery represents a promising alternative to systemic administration for local delivery of therapeutic antibodies in lung cancer treatment.

Published
2008

28. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization

Author

Maillet, A., Congy-Jolivet, Nicolas, Le Guellec, S., Vecellio, L., Hamard, S., Courty, Yves, Courtois, A., Gauthier, F., Diot, P., Thibault, Gilles, Lemarie, E., Heuzé-Vourc'h, N., Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), and Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio]
Published
2008

30. Impact d’une stratégie de prévention basée sur la pollution par l’ozone sur la santé de patients atteints d’insuffisance respiratoire

Author

Lacour, Sandrine, Veron, N, De Monte, M, Brocca, J, Le Guellec, S, Deprez, PH, Diot, P, Leblond, Valérie, Unité mixte de recherche biologie moléculaire et immunologie parasitaires et fongiques, Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire d'Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Inconnu, ProdInra, Migration, and Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire - Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2007

31. Impact of a prevention strategy with regard to ozone pollution on the health of respiratory insufficient patients

Author

Lacour, Sandrine, Veron, N, Brocca, J, Le Guellec, S, de Monte, M, Deprez, Ph, Diot, P, Leblond, Valérie, Unité mixte de recherche biologie moléculaire et immunologie parasitaires et fongiques, Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire d'Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Inconnu, Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire - Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2007

32. An efficient prevention strategy about ozone pollution

Author

Lacour, Sandrine, Veron, N, Brocca, J, Le Guellec, S, De Monte, M, Deprez, PH, Diot, P, Leblond, Valérie, Unité mixte de recherche biologie moléculaire et immunologie parasitaires et fongiques, Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire d'Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Inconnu, ProdInra, Migration, and Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire - Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2006

33. Abstract P3-14-13: eIF4E/4EBP1 axis and response to neoadjuvant trastuzumab-based treatment in HER2+ breast cancer – Results of a multicentre French retrospective cohort

Author

Dalenc, F, primary, Le Guellec, S, additional, Arnould, L, additional, Coudert, B, additional, Vagner, S, additional, Bachelot, T, additional, Treilleux, I, additional, Debled, M, additional, MacGrogan, G, additional, Jacot, W, additional, Bibeau, F, additional, Vanlemmens, L, additional, André, F, additional, Mathieu, M-C, additional, Augereau, P, additional, Verriele, V, additional, Penault-Llorca, F, additional, Lacroix-Triki, M, additional, and Filleron, T, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results